Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 23 May 2017
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Rituximab (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Acronyms S-BR
- 07 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 1 Feb 2018 to 17 May 2017.
- 18 May 2017 Planned primary completion date changed from 1 Feb 2018 to 17 May 2017.